Ocrelizumab – Primary Progressive Multiple Sclerosis

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

ocrelizumab

Ocrelizumab is a humanized monoclonal antibody currently under clinical investigation and development by the Swiss pharmaceutical company Roche. The therapy is targeted against mature B-lymphocytes with CD20 markers on their surface, giving the drug an immunosuppressive function that might be useful in normalizing the rates of immune attacks made by the host’s immune system against its own myelinated neurons, which form the main pathogenesis of multiple sclerosis (MS).

Read more: http://bit.ly/1JUBLqj

Print This Page

About the Author

Marta Ribeiro avatar
Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Tags

Multiple Sclerosis (MS), Ocrelizumab

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here

Survey Icon

Video

Recent Posts

Recommended reading